Hereditary Angioedema (HAE) Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4451360
  • Report
  • Region: Global
  • 105 pages
  • P&S Market Research
1 of 4

HAE currently exhibits a proliferating pipeline with 20 drug candidates.

HAE Therapeutics Pipeline in 2017

The study analyzed that HAE therapeutics pipeline comprises 20 drug candidates in different stages of development. HAE is a disease characterized by repeated incidents of swelling (angioedema). Some of the common body areas that get affected due to this disease include intestinal tract, face, limbs, and airway. The stress can cause a heart attack, but most often in the patients suffering from HAE, the swelling occurs with an unknown trigger.

Insights on pipeline segments

According to the research findings, most of the drug candidates of the HAE are being derived from the natural sources. The natural sources consist of various molecules such as gene therapies, biologicals, and RNA.

Technological Advancements for Drug Development to Boost the HAE Pipeline Growth

Most of the companies have developed novel technologies for the development of drug candidates for the treatment of HAE. For instance, Arrowhead Pharmaceuticals, Inc. has established a drug discovery, and development platform that has broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies. These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk, relative to traditional approaches. These technological advancements act as a key driver for pipeline growth.

Positive Clinical Results of HAE Therapeutics Candidates

The positive clinical results of HAE drug candidates are driving the pipeline growth. For instance, Attune Pharmaceuticals, Inc., announced the Pre-Clinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of HAE. Studies demonstrated that ATN-249 was highly selective and potent at plasma kallikrein inhibition in both biochemical inhibition and contact activation assays. Therefore, the positive clinical results of the compounds under the development for the treatment of HAE, are fueling the research and development investment being made by the players developing drugs for the treatment of HAE.

Some of the key players developing drugs for the treatment of HAE therapeutics include Shire plc, BioCryst Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc.

HAE Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 4

Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase III: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Pre-Clinical: Drug profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Strategic Development
5.4.4 Designation
5.4.5 Grants
5.4.6 Patent
5.4.7 Technology
5.5 Discovery: Drug profiles
5.5.1 Strategic Development
5.5.2 Designation
5.5.3 Grants
5.5.4 Patent
5.5.5 Technology

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Hereditary Angioedema (HAE) Therapeutics Pipeline
7.2 SWOT Analysis of Hereditary Angioedema (HAE) Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

Chapter 8. Company Profiles
8.1 Business Overview
8.2 Pipeline Products

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Pipeline Analysis Of Hereditary Angioedema (Hae) Therapeutics, By Company (2017)
Description Of Phase III Drug Candidates
Clinical Trials Of Phase III Drug Candidates
Description Of Phase II Drug Candidates
Clinical Trials Of Phase II Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Companies - at a Glance

List of Figures
Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Hae Therapeutics Drug Candidates Under Development (2017)
Hae Therapeutics Pipeline Split, By Molecule Type (2017)
Hae Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Swot Analysis

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • BioCryst Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Shire plc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll